Top Biotech Companies in Toronto (64)
Xylem |ˈzīləm| 1) The tissue in plants that brings water upward from the roots; 2) a leading global water technology company. Xylem, a leading global water technology company dedicated to solving the world’s most challenging water issues, is the leading global provider of efficient, innovative and sustainable water technologies improving the way water is used, managed, conserved and re-used. Our international team is...
Centricity Research is an integrated research organization (IRO) with more than 40 wholly owned and integrated clinical research offices across North America. The company conducts Phase I-IV clinical research in over 35 therapeutic areas: inpatient and outpatient; pharmaceutical, biotechnology, and medical device trials. For more than 25 years, the organization’s founders have worked to revolutionize research by investing in the...
Pontosense is fundamentally changing technology by expanding the relationship between humans and machines. Our passion for innovation pushes the boundaries of wireless sensing further than ever, leading to global partnerships and applications across several industries, including mobility, Age Tech, and smart homes. Our contactless AI solution uses mmWave RADAR to ensure the safety of your loved ones. It is the only...
Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies. The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. At Deep Genomics, our geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using our biologically accurate artificial intelligence technology.
University Health Network is Canada's largest research hospital and a public research and teaching hospital network in Toronto, Ontario, known for its scope of research and complexity of cases.
Rakuten Medical, Inc. is a global clinical stage biotechnology company developing and commercializing precision, cell-targeting investigational therapies on its AlluminoxTM platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Outside of Japan, Alluminox therapies have not yet been approved as safe or effective by any regulatory authority. The company’s first drug...
AmacaThera is a Toronto-based biotechnology company focused on developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications. Based on the research of world-renowned biomaterials scientist, Dr. Molly Shoichet, AmacaThera is commercializing combination products at the interface of biomaterials and pharmaceuticals. We have developed a platform technology which addresses the critical problem of sustaining...
10,000 people, one global focus - enhancing the health and well-being of pets, people, and livestock. We are passionate about what we do at IDEXX – and why wouldn’t we be? When you’re working to raise the standard of care for pets, make drinking water safe for billions and keep our livestock population around the globe healthy and free of...
IDEXX's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show double‑digit top‑line increases in 2025 and early 2026, with Q1 and Q2 2026 up 14% and 10% reported, respectively, and full‑year 2026 revenue guidance raised. Growth is broad‑based across Companion Animal Group diagnostics, Water, and LPD.
Profitability: Margin expansion is attributed to recurring diagnostics volume, pricing, and productivity, translating into higher EPS and operating leverage. Guidance and quarterly updates highlight continued earnings growth if these drivers are maintained.
Strong Market Position & Advantage: The company is widely regarded as the category leader in companion‑animal diagnostics, reinforced by an integrated ecosystem of instruments, consumables, labs, imaging, and software. Independent analyses consistently place it at or near the top across key diagnostics segments, supporting durable advantage.
Profound Change Requires Boldness. Johnson & Johnson is the largest and most broadly based healthcare company in the world. We’re producing life-changing breakthroughs every day, and have been for the last 130 years. The combination of new technologies and your expertise enables amazing things to happen. Teams from J&J’s consumer business are creating digital tools to help people track the...
Johnson & Johnson's Top Stability & Growth Strengths
Strong Revenue Growth: Companywide sales are described as increasing year over year, with momentum exiting 2025 and guidance calling for continued expansion into 2026.
Innovation-Driven Growth: Growth is attributed to innovative medicines and new product submissions, with oncology and immunology performance highlighted as key contributors.
Diversified Revenue Streams: The business is positioned around two large segments—Innovative Medicine and MedTech—creating a broader platform that helps offset declines in specific products.
MMR Consulting Inc. and its dedicated team of experienced consultants are committed to delivering high quality, robust solutions for the Pharmaceutical and Biotechnology industries. Our expertise includes Engineering (Process, Automation, Facilities), Capital Project Management of large/complex projects and programs, Commissioning Qualification Validation, and GMP Compliance services.
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.
Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.
Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.
BenchSci’s vision is to bring novel medicine to patients 50% faster by 2025. To achieve this, we're exponentially increasing the speed and quality of life-saving research by empowering scientists with the world’s most advanced biomedical artificial intelligence. Backed by F-Prime, Gradient Ventures (Google’s AI fund), Inovia Capital, and TCV, our platform accelerates science at 16 of the top-20 pharmaceutical companies, and...
Affinity Biologicals, Inc. is a primary manufacturer of products used worldwide in thrombosis and hemostasis research and diagnostics. Our products include an extensive line of antibodies, conjugates, antibody pairs for immunoassay of human and animal analytes, the VisuLize line of complete ELISA kits, and a full line of human plasma products including VisuDep Immune-Depleted Factor-Deficient Plasmas, VisuCal Calibrator Plasma and...
Ashfield Advisory is a business unit that provides integrated advisory and consulting services to the healthcare industry, leveraging an ecosystem of specialized businesses for insight, strategy, and action.
Avicanna is a Canadian international commercial-stage biopharmaceutical company. Focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development that has led to the commercialization of more than thirty products across five market segments: MyMedi.ca Medical Cannabis Care Portal, Medical Cannabis & Wellness...
Novel Biotechnology is a Synthetic Biology company focused on developing highly productive pDNA manufacturing platform. We also provide CRDMO and plasmid DNA manufacturing services to our clients
Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases—often with limited or no options—so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give...
Jazz Pharmaceuticals, Inc's Top Stability & Growth Strengths
Strong Market Position & Advantage: Jazz is described as a clear leader in rare sleep disorders through its oxybate franchise (Xywav/Xyrem and authorized generics royalties) and in cannabinoid-based epilepsy with Epidiolex surpassing $1B in 2025. Xywav’s idiopathic hypersomnia approval with orphan exclusivity and category-leading revenue reinforce defensibility.
Strong Revenue Growth: Record 2025 revenue around $4.27 billion and a record Q4, with 2026 guidance still pointing up, indicate sustained top-line momentum. Company communications highlight a multi-year streak of annual growth continuing into 2026.
Diversified Revenue Streams: A balanced base with rare sleep revenues above $2B, Epidiolex above $1B, and roughly $1.13B in oncology plus new contributions from Modeyso and royalties shows multiple revenue pillars. Pipeline drivers like zanidatamab and Zepzelca label expansion add additional avenues.
Established in the mid 1970's, New England Biolabs, Inc. (NEB) is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic...
Reunion Neuroscience is committed to innovating therapeutic solutions to treat mental health conditions through the development of novel psychedelic compounds
Geneseeq is a research-driven company providing cutting-edge next-generation sequencing (NGS) technology to accelerate precision cancer care. We offer both pan-cancer panels analyzing 400+ genes and cancer-type-specific gene panels for all sample types to help match a patient to the optimal treatment, including targeted therapy and immunotherapy for solid tumors and blood cancers. Additionally, we develop cutting-edge technologies and kits for...
